1232
Moderna’s mRNA cancer vaccine works even better than thought
(www.freethink.com)
you are viewing a single comment's thread
view the rest of the comments
view the rest of the comments
this post was submitted on 02 Jan 2024
1232 points (98.3% liked)
Technology
59559 readers
2245 users here now
This is a most excellent place for technology news and articles.
Our Rules
- Follow the lemmy.world rules.
- Only tech related content.
- Be excellent to each another!
- Mod approved content bots can post up to 10 articles per day.
- Threads asking for personal tech support may be deleted.
- Politics threads may be removed.
- No memes allowed as posts, OK to post as comments.
- Only approved bots from the list below, to ask if your bot can be added please contact us.
- Check for duplicates before posting, duplicates may be removed
Approved Bots
founded 1 year ago
MODERATORS
No it will be more expensive. The pricing would be based on how much it currently costs, priced competitively (95% of, say, $500,000) and then they'd add $500,000 to account for the fact that you would recover more of your life and avoid suffering, so $950k total. Of course they may simply price is based on the value of your life. Say the average value of a human is $1.5M in a typical wrongful death suit; they might price it at $1.25M - a bargain!.
Before you laugh at my logic, I'll point out that Luxturna priced their retinal degeneration drug based on how much value courts placed on lost eyesight. They found that to be around the million-dollar range. The price of treatment was then set at $850,000, because that's clearly providing value over the monetary equivalent of loss of eyesight (Jeffrey Marrazzo, CEO, was quoted in an interview that this was the basis). Of course, there's an evilly fun MBA discussion to be had, as well, as your pricing could also be how much it's worth to a parent not to have to watch their children slowly and unavoidably go blind as they become teenagers. Other drugs are often based on the cost avoidance or value of human life of 100-150k per year, and I'm sure they will argue that a cure should account for the entire life amortization of such a cost. Maybe it will be $5M for someone in their 20s, but only $500k for someone in their 70s.
If this is how they price these things, then why wasn't cancer treatment already $1.25M? Did they only just now realize how much they could squeeze out of people?
Luxturna's treatment is for a very rare form of blindness. Unfortunately treatments for rare diseases tend to be very expensive because of how R&D and the market works, there's much less opportunity to spread out the cost and mass production never happens. Melanoma is not a rare disease, unfortunately quite the opposite. Cancer in general even less so.
In many cases,in the US, the rack rate for a full course of a serious cancer is easily the $500k I suggested and frequently more than double that. My treatment for a suspected single point melanoma was close to $75,000 and it was a single outpatient procedure with a pre- and post-op office follow up. No chemo, no stage designation, nothing - zero cancer found at the site of the questionable biopsy site.
It’s true the Luxturna is an odd case (though the OP article is talking about customized treatment so it is appropriate here). It’s not the disease or cure but the justification of how they determined the cost of their treatment. Not based on the research cost or market, not based on the production or application of the treatment, but on the value of your eyesight they would be preserving.